Latest Funding News

Vertex Minerals launches a $2.5 million Share Purchase Plan at $0.10 per share, offering eligible shareholders a chance to invest ahead of commercial gold production at Reward Gold Mine.

Black Rock Mining has secured an extension of its US$204 million debt facility to November 2026, providing more time to finalise equity funding for the Mahenge Graphite Project in Tanzania.

Kinetiko Energy has approved a Field Development Plan marking its shift from exploration to production at the Brakfontein gas project in South Africa, aiming to fast-track gas output and secure strategic funding.

Nido Education Limited has secured a 12-month extension on its NAB loan facility, increasing available funding by $10 million and raising its bank guarantee capacity to $17.5 million, underpinning its growth in early childhood education.

Strategic Elements has achieved a significant milestone with the granting of a patent in Japan for its Energy Ink™ moisture energy platform, reinforcing its foothold in a critical electronics market and advancing its battery-free device ambitions.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.

West Wits Mining has locked in a R875 million (~USD 53 million) senior loan facility, receiving an initial R339 million drawdown that fully funds its Qala Shallows project through to steady-state gold production of 70,000 ounces per annum.

Global X Management (AUS) Limited is trimming the management fee for its Australia 300 ETF (ASX: A300) by 25%, effective 1 July 2026, reflecting a subtle but meaningful cost saving for investors.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.

Beetaloo Energy reports promising flow testing from Carpentaria-5H with sustained gas rates and low decline, while its Carpentaria Gas Plant construction remains on schedule for first gas sales in late 2026.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.